China's First Interventional Brain-Computer Interface Trial Shows Promise
China Achieves Breakthrough in Brain-Computer Interface Technology
A research team from Nankai University has successfully completed China's first clinical trial of an interventional brain-computer interface (BCI) to assist paralyzed patients. The trial resulted in significant motor function recovery for a 67-year-old patient who had been bedridden for over six months following multiple cerebral infarctions.
Patient Shows Remarkable Progress
The patient, Mr. Zheng, participated in the clinical trial beginning in June 2025. After approximately three months of rehabilitation training with the BCI system, he has regained the ability to walk with a cane and perform basic tasks like drinking water independently.
Innovative Minimally Invasive Approach
The technology, called an "intravenous brain-computer interface," represents a significant advancement in BCI methods:
- Uses electrodes thinner than human hair implanted via blood vessels
- Employs biocompatible titanium alloy materials
- Collects brain signals without open-brain surgery
- Currently undergoing multi-center clinical trials
The approach has been included in China's "Ethical Guidelines for Brain-Computer Interface Research" issued by the Ministry of Science and Technology.
Regulatory and Industry Developments
The National Medical Products Administration recently approved China's first medical device standard for BCI technology, set to take effect January 1, 2026. This milestone follows the August release of "Opinions on Promoting the Innovation and Development of the Brain-Computer Interface Industry" by seven government departments including the Ministry of Industry and Information Technology.
The policy sets ambitious goals:
| Year | Development Target |
|---|
Key Points:
- First successful clinical trial of interventional BCI in China shows promising results for paralysis treatment
- Minimally invasive approach reduces risks compared to traditional brain implants
- Government support growing with new standards and development policies
- Potential applications include treatment for stroke, paralysis, and ALS patients
